Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 22, 2023 | June 23, 2023 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director · Chief Executive Officer | March 15, 2017 | March 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date June 22, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.99 · Expires 2033-06-22 | Direct | 1,200 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,200 · Balance 1,200 F1: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 22, 2023, with the first quarterly installment vesting on September 22, 2023, subject to continued service on the company's Board of Directors through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 22, 2023, with the first quarterly installment vesting on September 22, 2023, subject to continued service on the company's Board of Directors through each vesting date.
TENAX THERAPEUTICS, INC.
Report date March 15, 2017 · Filed March 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,282,932 |
Ending reported balance
After 2017-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-03-15 · Grant · Acquired 213,420 · Balance 1,379,931 F1: Represents shares of common stock issued as payment of a portion of Mr. Kelley's bonus set forth in his employment agreement. Row 2 · 2017-03-15 · Tax withholding · Disposed 96,999 · Balance 1,282,932 F2: Represents shares withheld in satisfaction of tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued as payment of a portion of Mr. Kelley's bonus set forth in his employment agreement.
F2: Represents shares withheld in satisfaction of tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2023 Filed Jun 23, 2023 17:36 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 1,200 | $0.00 Strike: $12.99 | $0.00 |
DisclosureSEC source: 0001209191-23-039479 · doc4.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2033-06-22 F1 · derivative.exercise_date: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 22, 2023, with the first quarterly installment vesting on September 22, 2023, subject to continued service on the company's Board of Directors through each vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 08:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 10,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001209191-22-036573 · doc4.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-10 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 10, 2022, with the first quarterly installment vesting on September 10, 2022. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 07:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 10,000 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001209191-21-038108 · doc4.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 16:58 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001209191-20-037303 · doc4.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 15, 2020, with the first quarterly installment vesting on September 15, 2020. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 07:55 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $7.54 | $0.00 |
DisclosureSEC source: 0001209191-19-038364 · doc4.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 19, 2019, with the first quarterly installment vesting on September 19, 2019. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 07:46 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $28.15 | $0.00 |
DisclosureSEC source: 0001209191-18-039991 · doc4.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 09:02 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantNon-Employee Stock Option · Derivative | 15,000 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001209191-17-036992 · doc4.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on May 31, 2017, with the first quarterly installment vesting on August 31, 2017. Read SEC document |
| March 15, 2017 Filed Mar 20, 2017 23:29 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Tax withholdingCommon Stock | 96,999 | $0.68 | $65,959.32 |
DisclosureSEC source: 0001354488-17-000426 · issuerdirect_section16.xml · nonDerivative · entry 2 Kelley John P · CIK 0001310470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,932 F2 · shares: Represents shares withheld in satisfaction of tax withholding obligations. Read SEC document |
| March 15, 2017 Filed Mar 20, 2017 23:29 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantCommon Stock | 213,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000426 · issuerdirect_section16.xml · nonDerivative · entry 1 Kelley John P · CIK 0001310470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,379,931 F1 · shares: Represents shares of common stock issued as payment of a portion of Mr. Kelley's bonus set forth in his employment agreement. Read SEC document |
| December 15, 2016 Filed Dec 20, 2016 20:13 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001354488-16-008683 · issuerdirect_section16.xml · derivative · entry 1 Kelley John P · CIK 0001310470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2026-12-15 F1 · derivative.exercise_date: This option vests and becomes exercisable in four equal annual installments beginning on December 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.